Page 2 - Assal Hellmer News Today

As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding

Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 -- Emergent BioSolutions...

GAITHERSBURG, Md., Jan. 09, 2024 -- Emergent BioSolutions , a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today...

GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing GAITHERSBURG, Md., November 24, 2023 - Emergent BioSolutions Inc. today confirmed...

GAITHERSBURG, Md., Nov. 24, 2023 -- Emergent BioSolutions Inc. today confirmed that on November 16, 2023, the New York Stock Exchange sent a notice that the company is not in compliance with...

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of  $M and Adjusted EBITDA of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08,...

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of  $(266)M and Adjusted EBITDA(2) of $20MUpdates...

GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the

The state’s collections since early 2020 now outpace that raised from booze sales. The money has been used on everything from buying an opioid reversal drug to funding a Girl Scouts program to fight human trafficking.